Literature DB >> 30184146

NCCN Asia Consensus Statement prostate cancer.

Shiro Hinotsu1, Mikio Namiki2, Seiichiro Ozono3, Hideyuki Akaza4.   

Abstract

The National Comprehensive Cancer Network, an NPO organization comprised of university hospitals and cancer centers in the US. The publication of clinical practice guidelines on the treatment, diagnosis, prevention and screening is one of important activities. Background factors of prostate cancer patients, such as the prevalence, age at the diagnosis and mortality are markedly different between Western countries and Asia. Thus, various factors should be taken into consideration at the treatment choice for individual patients. Experts from Asian countries were published as the Asia Consensus Statement. In this review, we explain important points of the Asia Consensus Statement such as differences in the epidemiological backgrounds of patients, differences in treatment options and differences in medical insurance systems.

Entities:  

Mesh:

Year:  2018        PMID: 30184146     DOI: 10.1093/jjco/hyy116

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  9 in total

Review 1.  Management algorithms for metastatic prostate cancer.

Authors:  Shawn Malone; Bobby Shayegan; Naveen S Basappa; Kim Chi; Henry J Conter; Robert J Hamilton; Sebastien J Hotte; Fred Saad; Alan I So; Laura Park-Wyllie; Huong Hew; Deanna McLeod; Geoffrey Gotto
Journal:  Can Urol Assoc J       Date:  2019-04-26       Impact factor: 1.862

2.  Gut environment changes due to androgen deprivation therapy in patients with prostate cancer.

Authors:  Akimasa Kure; Tomoya Tsukimi; Chiharu Ishii; Wanping Aw; Nozomu Obana; Gaku Nakato; Akiyoshi Hirayama; Haruna Kawano; Toshiyuki China; Fumitaka Shimizu; Masayoshi Nagata; Shinji Isotani; Satoru Muto; Shigeo Horie; Shinji Fukuda
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-04-13       Impact factor: 5.554

3.  The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer.

Authors:  Se Young Choi; Bumjin Lim; Byung Hoon Chi; Wonchul Lee; Jung Hoon Kim; Yoon Soo Kyung; Dalsan You; Choung-Soo Kim
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

4.  Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.

Authors:  Yu Wei; Junlong Wu; Weijie Gu; Jun Wang; Guowen Lin; Xiaojian Qin; Bo Dai; Hualei Gan; Dingwei Ye; Yao Zhu
Journal:  Oncologist       Date:  2020-03-19

Review 5.  Associating the risk of three urinary cancers with obesity and overweight: an overview with evidence mapping of systematic reviews.

Authors:  Jiyuan Shi; Liang Zhao; Ya Gao; Mingming Niu; Meili Yan; Yamin Chen; Ziwei Song; Xueni Ma; Peng Wang; Jinhui Tian
Journal:  Syst Rev       Date:  2021-02-17

Review 6.  Recommendations on Weight Loss and Healthy Lifestyle in Prostate Cancer Clinical Guidelines: A Systematic Review.

Authors:  Mario Rivera-Izquierdo; Virginia Martínez-Ruiz; José Juan Jiménez-Moleón
Journal:  Int J Environ Res Public Health       Date:  2022-01-27       Impact factor: 3.390

7.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer.

Authors:  R Kanesvaran; E Castro; A Wong; K Fizazi; M L K Chua; Y Zhu; H Malhotra; Y Miura; J L Lee; F L T Chong; Y-S Pu; C-C Yen; M Saad; H J Lee; H Kitamura; K Prabhash; Q Zou; G Curigliano; E Poon; S P Choo; S Peters; E Lim; T Yoshino; G Pentheroudakis
Journal:  ESMO Open       Date:  2022-07-04

Review 8.  Epidemiology and genomics of prostate cancer in Asian men.

Authors:  Yao Zhu; Miao Mo; Yu Wei; Junlong Wu; Jian Pan; Stephen J Freedland; Ying Zheng; Dingwei Ye
Journal:  Nat Rev Urol       Date:  2021-03-10       Impact factor: 14.432

9.  The association between body mass index and the risk of different urinary cancers: Protocol for an overview of systematic reviews.

Authors:  Wenli Zhao; Jiyuan Shi; Yamin Chen; Ziwei Song; Liangliang Si; Xin Jiang; Yu Gu
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.